Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT01581294
Recruiting Observational

The Norwegian Antirheumatic Drug Register

NCT01581294 · tracked via the Priya Life Science Norway tracker
Sponsor
Diakonhjemmet Hospital
Phase
Observational
Started
2012-04
Last updated
2022-08-23

Condition(s) studied

Inflammatory Joint Diseases

Study summary

NOR-DMARD is a register-based longitudinal observational study of which the main objectives are to study the effectiveness of treatment of inflammatory joint diseases with biological disease modifying anti-rheumatic drugs (DMARDs) in clinical practice, by measuring disease activity, health related quality of life, function and joint damage, and to study the long-term safety of such treatment. Other objectives include the assessment of cost-effectiveness of treatment, to identify and and validate clinical, genetic and immunological predictors of efficacy and adverse events, to assess the impact of treatment with biological DMARDs on work participation and work productivity, to investigate different strategies for use of biological DMARDs, to assess the performance of different outcome measures, and to ensure a systematic and timely follow-up of patients treated with biological DMARDs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years * Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis * Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor Exclusion Criteria: * Unwillingness or unability to give written informed consent * Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible * Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol

Trial sites (6)

FacilityCityRegionStatus
Vestre Viken HF Drammen Hospital Drammen Buskerud Completed
Lillehammer Hospital for Rheumatic Diseases Lillehammer Oppland Recruiting
Førde Hospital Førde Sogn Og Fjordane Recruiting
St. Olavs Hospital Trondheim Sør-Trøndelag Completed
University Hospital of Northern Norway Tromsø Troms Recruiting
Diakonhjemmet Hospital Oslo Norway Recruiting

More Diakonhjemmet Hospital trials in Norway

Early STratification of Acute ARThritis Recruiting
The Remote Monitoring of Gout Feasibility Study in Primary Care Recruiting
RehabNytte - A Study of Rehabilitation Processes in Specialized Care in Norway Active, not recruiting
The Remote Monitoring of Gout Study Enrolling by invitation
Methotrexate in Erosive Inflammatory Hand Osteoarthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01581294 on ClinicalTrials.gov ↗ ← All trials in Norway